Homoharringtonine

Phase 3Small molecule

Ascentage Pharma Group Inc.

Homoharringtonine is one of 224 small molecule programs targeting Acute Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

223

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute LeukemiaActive, not recruiting

AML, AdultRecruiting

Elderly PatientsRecruiting

Induction TherapyRecruiting

T-ALLRecruiting

Prostate CancerRecruiting

Acute Myeloid LeukemiaRecruiting

Diffuse Large B-Cell LymphomaNot yet recruiting

Newly DiagnosedRecruiting

AMLRecruiting

Acute LeukemiaPreclinical

Active, not recruiting

AML, AdultPreclinical

Recruiting

Elderly PatientsPhase 2

Recruiting

Induction TherapyPhase 2

Recruiting

T-ALLPhase 2

Recruiting

Prostate CancerPhase 2

Recruiting

Acute Myeloid LeukemiaPhase 3

Recruiting

Diffuse Large B-Cell LymphomaPhase 2

Not yet recruiting

Newly DiagnosedPhase 3

Recruiting

AMLPhase 3

Recruiting

Showing 10 of 11 indications

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Paraplatin

AAvyxa

Phase 3

25 2

Nizoral

WWim Janssens

Phase 3

21 3

Alinamin

Roche

Phase 3

6 4

Homoharringtonine

Ascentage Pharma Group Inc.

Phase 3

1 5

Triptorelin Embonate

Ipsen

Phase 3

3 6

Lhrha

Johnson & Johnson

Phase 3

2 7

Piflufolastat

Novartis

Phase 3

2 8

AAA817

Novartis

Phase 3

1 9

Luteinizing Hormone Releasing Hormone

UUS Department of Veterans Affairs

Phase 3

2 10

Trexall

Jazz Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Newly Diagnosed

NCT06361329

Q2 2027

Phase 2Recruiting

Elderly Patients

NCT06744556

Q4 2027

Phase 2Recruiting

Prostate Cancer

NCT07163910

Q1 2028

Phase 2/3Recruiting

AML

NCT05805098

Clinical

Trials by Indication[1]

AML3 trials

Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML

Unknown status·GGe Zheng·Phase 2·NCT04248595·100 enrolled

Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML

Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2/3·NCT05805098·60 enrolled

Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Preclinical·NCT06265545·458 enrolled

Myeloid Leukemia2 trials

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Completed· Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.·Phase 2·NCT04126681·144 enrolled

Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)

Terminated·CChemGenex Pharmaceuticals·Phase 2·NCT00114959·15 enrolled

Newly Diagnosed2 trials

Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 3·NCT06361329·81 enrolled

VAH vs VA in Newly Diagnosed Elderly AML

Not yet recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 3·NCT07469046·308 enrolled

Induction Therapy1 trial

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

Recruiting·—·Phase 2·NCT06221683·500 enrolled

Acute Promyelocytic Leukemia1 trial

Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia

Withdrawn·NNational Cancer Institute (NCI)·Phase 1/2·NCT00030355

10 more indications

Chronic Myelogenous Leukemia1 trial

Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa

Terminated·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00004933·5 enrolled

Not yet recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 1/2·NCT07159906·62 enrolled

Acute Myeloid Leukemia1 trial

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Recruiting·SShanxi Bethune Hospital·Phase 3·NCT05726110·50 enrolled

Pediatric1 trial

Newly-diagnosed Pediatric T-cell ALL Protocol

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2/3·NCT06855810·610 enrolled

Prostate Cancer1 trial

Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study

Recruiting·Bbaotai Liang·Phase 2·NCT07163910·93 enrolled

Acute Myeloid Leukemia (AML)1 trial

A Multi-Center, Prospective, Open-Label, Single-Arm Study of Homoharringtonine Combined With Lisaftoclax and Azacitidine in Patients With Acute Myeloid Leukemia After Failure of Venetoclax-Based Therapy

Enrolling by invitation·GGuangdong Second Provincial General Hospital·Phase 2·NCT07813390·73 enrolled

AML, Adult1 trial

MRD-positive AML: a Prospective, Single-arm, Multicenter Platform Clinical Study

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Preclinical·NCT07131059·537 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for Homoharringtonine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Homoharringtonine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Homoharringtonine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ascentage Pharma Group Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Ascentage Pharma Group Inc.

Homoharringtonine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q4 2027

Q1 2028

Trials by Indication[1]

AML3 trials

Myeloid Leukemia2 trials

Newly Diagnosed2 trials

Induction Therapy1 trial

Acute Promyelocytic Leukemia1 trial

Chronic Myelogenous Leukemia1 trial

Acute Leukemia1 trial

Elderly Patients1 trial

T-ALL1 trial

Diffuse Large B-Cell Lymphoma1 trial

Acute Myeloid Leukemia1 trial

Pediatric1 trial

Prostate Cancer1 trial

Acute Myeloid Leukemia (AML)1 trial

AML, Adult1 trial

References

Drug Info

Quick Facts

Related News